- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00941018
Single and Multiple Ascending Oral Dose Study of RX-10001 in Healthy Volunteers
December 1, 2009 updated by: Resolvyx Pharmaceuticals, Inc
A Randomized, Double Blind, Placebo Controlled, Ascending Single and Multiple Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Food Effect Study of RX-10001 in Healthy Volunteers
This study is being conducted to determine the safety, tolerability, pharmacodynamics and pharmacokinetics of RX-10001.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
56
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Zuidlaren, Netherlands, 9471 GP
- PRA International
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- BMI: 18 - 32 kg/m2, inclusive
- Female subjects: must be of non-childbearing potential (either surgically sterilized or at least 1 year post-menopausal (amenorrhea duration of 12 months)
- Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, "power drinks") and grapefruit (juice) from 48 h prior to entry in the clinical research center until discharge
- Medical history without major pathology
- Resting supine blood pressure and pulse rate showing no clinically relevant deviations as judged by the MI
- Computerised (12-lead) ECG recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the MI
- All values for hematology and for clinical chemistry tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the MI
- Willingness to sign the written Informed Consent Form (ICF)
Exclusion Criteria:
- Evidence of clinically relevant pathology
- Mental handicap
- History of relevant drug and/or food allergies
- Regular/routine treatment with non-topical medications within 30 days prior to drug administration
- Use of tobacco products (less than 60 days prior to drug administration)
- History of alcohol abuse or drug addiction (including soft drugs like cannabis products)
- Use of concomitant medication (including over the counter medication, health supplements, multivitamins and vitamin C, vitamin and omega-3 supplements, and herbal remedies such as St. John's Wort extract) must have been stopped at least 14 days prior to the first dose. The use of a limited amount of acetaminophen (paracetamol) is permitted on discretion of the MI.
- Participation in a drug study within 60 days prior to drug administration. Participation in more than 3 other drug studies in the 10 months preceding the start of this study.
- Donation of more than 100 mL of blood within 60 days prior to drug administration. Donation of more than 1.5 litres of blood in the 10 months preceding the start of this study.
- Positive screen on drugs of abuse (opiates, methadone, cocaine, amphetamines, cannabinoids), barbiturates, benzodiazepines, tricyclic antidepressants and alcohol
- Intake of more than 24 units of alcohol per week (one unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)
- Positive screen on HBsAg
- Positive screen on anti HCV
- Positive screen on anti HIV 1/2
- Illness within 5 days prior to (the first) drug administration
- Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays of thorax and bony skeleton (excluding spinal column)), during work or during participation in a medical trial in the previous year
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: SAD cohort 1
Single ascending dose (SAD) cohort 1 will participate in three dosing periods separated by 2 weeks.
Eight subjects will be enrolled, 6 will receive RX-10001 and 2 will receive vehicle control.
The starting dose will be 300 mg.
Subsequent doses will be determined by the pk and safety data from previous cohorts.
|
RX-10001 or vehicle control will be administered as an oral solution.
Doses will be determined according to the pk results of the preceding cohorts.
|
EXPERIMENTAL: SAD cohort 2
SAD cohort 2 will participate in three dosing periods separated by 2 weeks.
Eight subjects will be enrolled, 6 will receive RX-10001 and 2 will receive vehicle control.
The doses to be administered will be determined by the pk and safety data from previous cohorts.
|
RX-10001 or vehicle control will be administered as an oral solution.
Doses will be determined according to the pk results of the preceding cohorts.
|
EXPERIMENTAL: MAD cohort 1
Multiple ascending dose (MAD) cohort 1 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control.
The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous SAD cohorts.
|
RX-10001 or vehicle control will be administered as an oral solution.
Doses will be determined according to the pk results of the preceding cohorts.
|
EXPERIMENTAL: MAD cohort 2
MAD cohort 2 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control.
The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohort.
|
RX-10001 or vehicle control will be administered as an oral solution.
Doses will be determined according to the pk results of the preceding cohorts.
|
EXPERIMENTAL: MAD cohort 3
MAD cohort 3 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control.
The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohorts.
|
RX-10001 or vehicle control will be administered as an oral solution.
Doses will be determined according to the pk results of the preceding cohorts.
|
EXPERIMENTAL: MAD cohort 4
MAD cohort 4 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control.
The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohort.
|
RX-10001 or vehicle control will be administered as an oral solution.
Doses will be determined according to the pk results of the preceding cohorts.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability following single and multiple ascending oral doses as assessed by adverse events, vital signs, 12-lead ECG, clinical laboratory and physical exam.
Time Frame: 1 and 7 days
|
1 and 7 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the pk and pharmacodynamics after single and multiple ascending doses
Time Frame: 1 and 7 days
|
1 and 7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Renger Tiessen, MD PhD, PRA Health Sciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2009
Primary Completion (ACTUAL)
September 1, 2009
Study Completion (ACTUAL)
September 1, 2009
Study Registration Dates
First Submitted
July 14, 2009
First Submitted That Met QC Criteria
July 16, 2009
First Posted (ESTIMATE)
July 17, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
December 2, 2009
Last Update Submitted That Met QC Criteria
December 1, 2009
Last Verified
December 1, 2009
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- RX-10001-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on RX-10001
-
Abbott Medical DevicesCompletedCarotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy (CANOPY)Stroke | Carotid Artery Disease | Amaurosis Fugax | Transient Ischemic Attack (TIA)United States
-
Abbott Medical DevicesCompleted
-
Atrium Medical CorporationCompletedHypertension, Renovascular | Renal Artery StenosisUnited States
-
Abbott Medical DevicesCompleted
-
Unity Health TorontoRecruitingMCI | Amnestic Mild Cognitive DisorderCanada
-
Processa PharmaceuticalsCompletedSolid Tumor | Metastatic Bladder CancerUnited States
-
Kaiser PermanenteUnity HealthActive, not recruitingPhysical Activity | Mental Health Wellness 1United States
-
C.T. Development America, Inc.Completed